| Literature DB >> 32514437 |
Michelle McCabe1, Yvonne Perner1, Rindidzani Magobo1, Sheefa Mirza2, Clement Penny2.
Abstract
BACKGROUND AND AIM: Epidemiological studies of colorectal cancer (CRC) in South Africa (SA) have been poorly characterized. Black and white SA population groups have demonstrated distinct CRC clinical presentations, suggesting that black SA patients follow a different carcinogenic pathway than their white counterparts. Thus, the aim of this study was to identify unique demographic and histopathological features associated with black SA patients to facilitate earlier diagnosis and to improve disease management.Entities:
Keywords: South Africa; colorectal cancer; descriptive epidemiology; race
Year: 2019 PMID: 32514437 PMCID: PMC7273728 DOI: 10.1002/jgh3.12248
Source DB: PubMed Journal: JGH Open ISSN: 2397-9070
Descriptive histopathological analysis of colorectal cancer cases diagnosed at Charlotte Maxeke Johannesburg Academic Hospital between 2011 and 2015: Black versus other race groups
| Stratified by race groups no. of cases (%) | ||||
|---|---|---|---|---|
| Demographic data | Number of cases (%) | Black (B) | Other race groups (O) | Statistical analysis: |
| Gender | 665 | 391 | 274 |
|
| Male | 366 (55) | 216 (55) | 150 (55) | |
| Female | 299 (45) | 175 (45) | 124 (45) | |
| Age | 660 | 389 | 271 |
|
| Median | 59 | 56 | 62 | |
| Min–Max | 15–94 | 15–94 | 25–92 | |
| Mean ± SD | 57 ± 14 | 55 ± 15 | 62 ± 13 | |
| P25‐P75 | 49–68 | 45–65 | 55–71 | |
| 95% CI | [56–59] | [53–56] | [60–64] | |
| ≤50 years | 184 (28) | 142 (37) | 42 (15) |
|
| >50 years | 476 (72) | 247 (63) | 229 (85) | |
| Tumor site | 621 | 368 | 253 |
|
| Left | 427 (69) | 250 (68) | 177 (70) | |
| Right | 190 (30) | 115 (31) | 75 (30) | |
| Left and right | 4 (1) | 3 (1) | 1 (0) | |
| Tumor subtype | 646 | 380 | 266 |
|
| Invasive adenocarcinoma | 596 (92) | 349 (92) | 247 (93) | |
| Mucinous adenocarcinoma | 29 (5) | 16 (4) | 13 (5) | |
| Signet ring cell adenocarcinoma | 20 (3) | 15 (4) | 5 (2) | |
| Neuroendocrine carcinoma | 1 (0) | 0 (0) | 1 (0) | |
| Tumor grade | 624 | 372 | 252 |
|
| LG | 568 (91) | 336 (90) | 232 (92) | |
| HG | 56 (9) | 36 (10) | 20 (8) | |
| AJCC TNM staging | 350 | 208 | 142 |
|
| I | 46 (13) | 26 (13) | 20 (15) | |
| II | 109 (31) | 59 (28) | 50 (35) | |
| III | 180 (52) | 114 (55) | 66 (46) | |
| IV | 15 (4) | 9 (4) | 6 (4) | |
| Tumor‐infiltrating lymphocytes | 345 | 202 | 143 |
|
| None | 224 (65) | 135 (67) | 89 (62) | |
| Mild–moderate | 121 (35) | 67 (33) | 54 (38) | |
| Crohn's‐like inflamatory response | 345 | 202 | 143 |
|
| None | 263 (76) | 158 (78) | 105 (73) | |
| Mild–moderate | 82 (24) | 44 (22) | 38 (27) | |
| Lymphatic invasion | 422 | 254 | 168 |
|
| Absent | 296 (70) | 172 (68) | 124 (74) | |
| Present | 126 (30) | 82 (32) | 44 (26) | |
| Polyps | 408 | 234 | 174 |
|
| Absent | 268 (66) | 160 (68) | 108 (62) | |
| Present | 140 (34) | 74 (32) | 66 (38) | |
| Polyp subtype | 140 | 75 | 65 |
|
| Hyperplastic polyp | 4 (3) | 1 (1) | 3 (5) | |
| Pseudopolyp | 2 (1) | 2 (3) | 0 (0) | |
| Sessile serrated adenoma | 1 (1) | 0 (0) | 1 (1) | |
| TA | 72 (51) | 43 (57) | 29 (45) | |
| TVA | 61 (44) | 29 (39) | 32 (49) | |
| TA grade | 67 | 39 | 28 |
|
| LG | 40 (60) | 25 (65) | 15 (54) | |
| HG | 27 (40) | 14 (35) | 13 (46) | |
| TVA grade | 60 | 28 | 32 | |
| LG | 11 (18) | 2 (7) | 8 (25) | |
| HG | 49 (82) | 25 (93) | 24 (75) | |
| BRAF V600E | 76 | 55 | 21 |
|
| Wild‐type | 71 | 55 (100) | 16 (76) | |
| Mutation | 5 | 0 (0) | 5 (24) | |
*Statistically significant.
***Statistically highly significant.
AJCC, American Joint Committee on Cancer; CI, confidence interval; HG, high grade; LG, low grade; TA, tubular adenoma; TNM, tumor node metastases; TVA, tubulovillous adenoma.
Descriptive histopathological analysis of colorectal cancer cases diagnosed at Charlotte Maxeke Johannesburg Academic Hospital between 2011 and 2015: Younger (≤50 years) versus older (>50 years) patients
| Stratified by age groups no. of cases (%) | ||||
|---|---|---|---|---|
| Demographic data | Number of cases (%) | ≤50 years | >50 years | Statistical analysis: |
| Gender | 665 | 189 | 476 |
|
| Male | 366 (55) | 114 (60) | 252 (53) | |
| Female | 299 (45) | 75 (40) | 224 (47) | |
| Age | 660 | 389 | 271 |
|
| Median | 59 | 41 | 64 | |
| Min–Max | 15–94 | 15–50 | 51–94 | |
| Mean ± SD | 57 ± 14 | 40 ± 8 | 65 ± 9 | |
| P25‐P75 | 49–68 | 34–46 | 57–71 | |
| 95% CI | [56–59] | [39–41] | [64–66] | |
| Tumor site | 621 | 179 | 442 |
|
| Left | 426 (68) | 119 (66) | 307 (69) | |
| Right | 191 (31) | 60 (34) | 131 (30) | |
| Left and right | 4 (1) | 0 (0) | 4 (1) | |
| Tumor subtype | 646 | 183 | 463 |
|
| Invasive adenocarcinoma | 596 (92) | 159 (87) | 437 (94) | |
| Mucinous adenocarcinoma | 29 (5) | 8 (4) | 21 (5) | |
| Signet ring cell adenocarcinoma | 20 (3) | 16 (9) | 4 (1) | |
| Neuroendocrine carcinoma | 1 (0) | 0 (0) | 1 (0) | |
| Tumor grade | 624 | 178 | 446 |
|
| LG | 568 (91) | 152 (85) | 416 (93) | |
| HG | 56 (9) | 26 (15)** | 30 (7) | |
| AJCC TNM staging | 350 | 100 | 250 |
|
| I | 46 (13) | 9 (9) | 37 (15) | |
| II | 109 (31) | 27 (27) | 82 (33) | |
| III | 180 (52) | 59 (59) | 121 (48) | |
| IV | 15 (4) | 5 (5) | 10 (4) | |
| Tumor‐infiltrating lymphocytes | 345 | 98 | 247 |
|
| None | 224 (65) | 72 (73) | 152 (62) | |
| Mild–moderate | 121 (35) | 26 (27) | 95 (38) | |
| Crohn's‐like inflamatory response | 345 | 98 | 247 |
|
| None | 263 (76) | 80 (82) | 183 (74) | |
| Mild–moderate | 82 (24) | 18 (18) | 64 (26) | |
| Lymphatic invasion | 422 | 120 | 302 |
|
| Absent | 296 (70) | 75 (63) | 221 (73) | |
| Present | 126 (30) | 45 (37) | 81 (27) | |
| Polyps | 408 | 111 | 297 |
|
| Absent | 268 (66) | 79 (71) | 189 (64) | |
| Present | 140 (34) | 32 (29) | 108 (36) | |
| Polyp subtype | 140 | 32 | 108 |
|
| Hyperplastic polyp | 4 (3) | 0 (0) | 4 (4) | |
| Pseudopolyp | 2 (1) | 1 (3) | 1 (1) | |
| Sessile serrated adenoma | 1 (1) | 0 (0) | 1 (1) | |
| TA | 72 (51) | 18 (56) | 54 (50) | |
| TVA | 61 (44) | 13 (41) | 48 (44) | |
| Polyp grade |
| |||
| TA | 67 | 18 | 49 | |
| LG | 40 (60) | 10 (56) | 30 (60) | |
| HG | 27 (40) | 8 (44) | 19 (40) | |
| TVA | 60 | 12 | 48 | |
| LG | 11 (18) | 3 (25) | 8 (17) | |
| HG | 49 (82) | 9 (75) | 40 (83) | |
| BRAF V600E | 76 | 40 | 36 |
|
| Wildtype | 71 | 40 (100) | 31 (76) | |
| Mutation | 5 | 0 (0) | 5 (24) | |
*Statistically significant.
***Statistically highly significant.
AJCC, American Joint Committee on Cancer; CI, confidence interval; HG, high grade; LG, low grade; TA, tubular adenoma; TNM, tumor node metastases; TVA, tubulovillous adenoma.
Descriptive histopathological analysis of colorectal cancer cases diagnosed at Charlotte Maxeke Johannesburg Academic Hospital between 2011 and 2015: Male versus female
| Stratified by gender no. of cases (%) | ||||
|---|---|---|---|---|
| Demographic data | Number of cases (%) | Male | Female | Statistical analysis: |
| Gender | 665 | 366 (55%) | 299 (45%) | |
| Age | 660 | 364 | 296 |
|
| Median | 59 | 58 | 60 | |
| Min–Max | 15–94 | 15–94 | 20–92 | |
| Mean ± SD | 57 ± 14 | 56 ± 14 | 59 ± 14 | |
| P25‐P75 | 49–68 | 47–67 | 51–69 | |
| 95% CI | [56–59] | [55–58] | [58–61] | |
| Tumor site | 621 | 344 | 277 |
|
| Left | 426 (68) | 237 (69) | 189 (68) | |
| Right | 191 (31) | 105 (31) | 86 (31) | |
| Left and right | 4 (1) | 2 (0) | 2 (1) | |
| Tumor subtype | 646 | 183 | 463 |
|
| Invasive adenocarcinoma | 596 (92) | 437 (87) | 267 (94) | |
| Mucinous adenocarcinoma | 29 (5) | 21 (4) | 14 (5) | |
| Signet ring cell adenocarcinoma | 20 (3) | 4 (9) | 9 (1) | |
| Neuroendocrine carcinoma | 1 (0) | 1 (0) | 0 (0) | |
| Tumor grade | 624 | 344 | 280 |
|
| LG | 568 (91) | 308 (85) | 260 (93) | |
| HG | 56 (9) | 36 (15) | 20 (7) | |
| AJCC TNM staging | 350 | 100 | 250 |
|
| I | 46 (13) | 9 (9) | 37 (15) | |
| II | 109 (31) | 27 (27) | 82 (33) | |
| III | 180 (52) | 59 (59) | 121 (48) | |
| IV | 15 (4) | 5 (5) | 10 (4) | |
| Tumor‐infiltrating lymphocytes | 345 | 192 | 153 |
|
| None | 224 (65) | 132 (69) | 92 (60) | |
| Mild–moderate | 121 (35) | 60 (31) | 61 (40) | |
| Crohn's‐like inflamatory response | 345 | 192 | 153 |
|
| None | 263 (76) | 154 (80) | 109 (71) | |
| Mild–moderate | 82 (24) | 38 (20) | 44 (29) | |
| Lymphatic invasion | 422 | 234 | 188 |
|
| Absent | 296 (70) | 162 (69) | 134 (71) | |
| Present | 126 (30) | 72 (31) | 54 (29) | |
| Polyps | 408 | 236 | 174 |
|
| Absent | 268 (66) | 147 (62) | 123 (71) | |
| Present | 140 (34) | 89 (38) | 51 (29) | |
| Polyp subtype | 140 | 89 | 51 |
|
| Hyperplastic polyp | 4 (3) | 3 (4) | 1 (2) | |
| Pseudopolyp | 2 (1) | 2 (2) | 0 (0) | |
| Sessile serrated adenoma | 1 (1) | 0 (0) | 1 (2) | |
| TA | 72 (51) | 43 (48) | 29 (57) | |
| TVA | 61 (44) | 41 (46) | 20 (39) | |
| Polyp grade |
| |||
| TA | 67 | 36 | 28 | |
| LG | 40 (60) | 21 (58) | 17 (54) | |
| HG | 27 (40) | 15 (42) | 11 (46) | |
| TVA | 60 | 41 | 19 | |
| LG | 11 (18) | 6 (15) | 5 (28) | |
| HG | 49 (82) | 35 (85) | 14 (72) | |
| BRAF V600E | 76 | 44 | 32 |
|
| Wildtype | 71 | 42 (95) | 29 (91) | |
| Mutation | 5 | 2 (5) | 3 (9) | |
*Statistically significant.
***Statistically highly significant.
AJCC, American Joint Committee on Cancer; CI, confidence interval; HG, high grade; LG, low grade; TA, tubular adenoma; TNM, tumor node metastases; TVA, tubulovillous adenoma.
Descriptive histopathological analysis of CRC cases diagnosed at Charlotte Maxeke Johannesburg Academic Hospital between 2011–2015: Left versus right‐sided colon cancer
| Stratified by tumor site no. of cases (%) | ||||
|---|---|---|---|---|
| Demographic data | Number of cases (%) | Left‐sided | Right‐sided | Statistical analysis: |
| Tumor site | 617 | 426 (69%) | 191 (31%) | |
| Tumor subtype | 607 | 419 | 188 |
|
| Invasive adenocarcinoma | 596 (92) | 398 (95) | 162 (86) | |
| Mucinous adenocarcinoma | 29 (5) | 9 (2) | 18 (10) | |
| Signet ring cell adenocarcinoma | 20 (3) | 12 (3) | 7 (4) | |
| Neuroendocrine carcinoma | 1 (0) | 0 (0) | 1 (0) | |
| Tumor grade | 587 | 399 | 188 |
|
| LG | 533 (91) | 366 (92) | 167 (89) | |
| HG | 54 (9) | 33 (8) | 21 (11) | |
| AJCC TNM staging | 350 | 192 | 153 |
|
| I | 46 (13) | 28 (15) | 17 (11) | |
| II | 109 (31) | 60 (31) | 46 (30) | |
| III | 180 (52) | 96 (50) | 80 (52) | |
| IV | 15 (4) | 8 (4) | 10 (7) | |
| Tumor‐infiltrating lymphocytes | 338 | 193 | 145 |
|
| None | 220 (65) | 136 (70) | 84 (58) | |
| Mild–moderate | 118 (35) | 57 (30) | 61 (42) | |
| Crohn's like inflamatory response | 338 | 193 | 145 |
|
| None | 258 (76) | 147 (76) | 111 (77) | |
| Mild–moderate | 80 (24) | 46 (24) | 34 (23) | |
| Lymphatic invasion | 417 | 254 | 163 |
|
| Absent | 293 (70) | 194 (76) | 99 (61) | |
| Present | 123 (30) | 60 (24) | 64 (39) | |
| Polyps | 392 | 231 | 161 |
|
| Absent | 261 (67) | 150 (65) | 111 (69) | |
| Present | 131 (33) | 81 (35) | 50 (31) | |
| Polyp subtype | 131 | 81 | 50 |
|
| Hyperplastic polyp | 3 (2) | 3 (4) | 0 (0) | |
| Pseudopolyp | 2 (1) | 0 (0) | 2 (4) | |
| Sessile serrated adenoma | 1 (1) | 0 (0) | 1 (2) | |
| TA | 68 (52) | 43 (53) | 25 (50) | |
| TVA | 57 (44) | 35 (43) | 22 (44) | |
| Polyp grade | 119 |
| ||
| TA | 64 | 40 | 24 | |
| LG | 38 (59) | 21 (52) | 17 (71) | |
| HG | 26 (41) | 19 (48) | 7 (29) | |
| TVA | 55 | 34 | 21 | |
| LG | 10 (18) | 3 (9) | 7 (33) | |
| HG | 45 (82) | 31 (91) | 14 (67) | |
| BRAF V600E | 76 | 42 | 34 |
|
| Wildtype | 71 | 42 (100) | 29 (85) | |
| Mutation | 5 | 0 (0) | 5 (15) | |
*Statistically significant.
***Statistically highly significant.
AJCC, American Joint Committee on Cancer; CI, confidence interval; CRC, colorectal cancer; HG, high grade; LG, low grade; TA, tubular adenoma; TNM, tumor node metastases; TVA, tubulovillous adenoma.